6,301 reports of this reaction
4.3% of all MESALAMINE reports
#3 most reported adverse reaction
COLITIS ULCERATIVE is the #3 most commonly reported adverse reaction for MESALAMINE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 6,301 FDA adverse event reports linking MESALAMINE to COLITIS ULCERATIVE. This represents approximately 4.3% of all 145,688 adverse event reports for this drug.
Patients taking MESALAMINE who experience colitis ulcerative should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLITIS ULCERATIVE is moderately reported among MESALAMINE users, representing a notable but not dominant share of adverse events.
In addition to colitis ulcerative, the following adverse reactions have been reported for MESALAMINE:
The following drugs have also been linked to colitis ulcerative in FDA adverse event reports:
COLITIS ULCERATIVE has been reported as an adverse event in 6,301 FDA reports for MESALAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLITIS ULCERATIVE accounts for approximately 4.3% of all adverse event reports for MESALAMINE, making it one of the most commonly reported side effect.
If you experience colitis ulcerative while taking MESALAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.